Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis

Ryan A. Hlady, Slavomira Novakova, Jana Opavska, David L Klinkebiel, Staci L. Peters, Juraj Bies, Jay Hannah, Javeed Iqbal, Kristi M. Anderson, Hollie M. Siebler, Lynette M Smith, Timothy Charles Greiner, Dhundy Raj Bastola, Shantaram S Joshi, Oksana Lockridge, Melanie A. Simpson, Dean W. Felsher, Kay Uwe Wagner, Wing C. Chan, Judith K. ChristmanRene Opavsky

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals. DNA methylation contributes to the epigenetic control of gene transcription and is deregulated in virtually all human tumors. To better understand the generation of cancer-specific methylation patterns, we genetically inactivated Dnmt3b in a mouse model of MYC-induced lymphomagenesis. Ablation of Dnmt3b function using a conditional knockout in T cells accelerated lymphomagenesis by increasing cellular proliferation, which suggests that Dnmt3b functions as a tumor suppressor. Global methylation profiling revealed numerous gene promoters as potential targets of Dnmt3b activity, the majority of which were demethylated in Dnmt3b -/- lymphomas, but not in Dnmt3b -/- pretumor thymocytes, implicating Dnmt3b in maintenance of cytosine methylation in cancer. Functional analysis identified the gene Gm128 (which we termed herein methylated in normal thymocytes [Ment]) as a target of Dnmt3b activity. We found that Ment was gradually demethylated and overexpressed during tumor progression in Dnmt3b -/- lymphomas. Similarly, MENT was overexpressed in 67% of human lymphomas, and its transcription inversely correlated with methylation and levels of DNMT3B. Importantly, knockdown of Ment inhibited growth of mouse and human cells, whereas overexpression of Ment provided Dnmt3b +/+ cells with a proliferative advantage. Our findings identify Ment as an enhancer of lymphomagenesis that contributes to the tumor suppressor function of Dnmt3b and suggest it could be a potential target for anticancer therapies.

Original languageEnglish (US)
Pages (from-to)163-177
Number of pages15
JournalJournal of Clinical Investigation
Volume122
Issue number1
DOIs
StatePublished - Jan 3 2012

Fingerprint

Thymocytes
Up-Regulation
Neoplasms
Methylation
Lymphoma
Cytosine
DNA methyltransferase 3B
Genes
DNA Methylation
Epigenomics
Mammals
Maintenance
Cell Proliferation
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. / Hlady, Ryan A.; Novakova, Slavomira; Opavska, Jana; Klinkebiel, David L; Peters, Staci L.; Bies, Juraj; Hannah, Jay; Iqbal, Javeed; Anderson, Kristi M.; Siebler, Hollie M.; Smith, Lynette M; Greiner, Timothy Charles; Bastola, Dhundy Raj; Joshi, Shantaram S; Lockridge, Oksana; Simpson, Melanie A.; Felsher, Dean W.; Wagner, Kay Uwe; Chan, Wing C.; Christman, Judith K.; Opavsky, Rene.

In: Journal of Clinical Investigation, Vol. 122, No. 1, 03.01.2012, p. 163-177.

Research output: Contribution to journalArticle

Hlady, RA, Novakova, S, Opavska, J, Klinkebiel, DL, Peters, SL, Bies, J, Hannah, J, Iqbal, J, Anderson, KM, Siebler, HM, Smith, LM, Greiner, TC, Bastola, DR, Joshi, SS, Lockridge, O, Simpson, MA, Felsher, DW, Wagner, KU, Chan, WC, Christman, JK & Opavsky, R 2012, 'Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis', Journal of Clinical Investigation, vol. 122, no. 1, pp. 163-177. https://doi.org/10.1172/JCI57292
Hlady, Ryan A. ; Novakova, Slavomira ; Opavska, Jana ; Klinkebiel, David L ; Peters, Staci L. ; Bies, Juraj ; Hannah, Jay ; Iqbal, Javeed ; Anderson, Kristi M. ; Siebler, Hollie M. ; Smith, Lynette M ; Greiner, Timothy Charles ; Bastola, Dhundy Raj ; Joshi, Shantaram S ; Lockridge, Oksana ; Simpson, Melanie A. ; Felsher, Dean W. ; Wagner, Kay Uwe ; Chan, Wing C. ; Christman, Judith K. ; Opavsky, Rene. / Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. In: Journal of Clinical Investigation. 2012 ; Vol. 122, No. 1. pp. 163-177.
@article{5cfa0b01409e466fae0f95ece4574edb,
title = "Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis",
abstract = "DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals. DNA methylation contributes to the epigenetic control of gene transcription and is deregulated in virtually all human tumors. To better understand the generation of cancer-specific methylation patterns, we genetically inactivated Dnmt3b in a mouse model of MYC-induced lymphomagenesis. Ablation of Dnmt3b function using a conditional knockout in T cells accelerated lymphomagenesis by increasing cellular proliferation, which suggests that Dnmt3b functions as a tumor suppressor. Global methylation profiling revealed numerous gene promoters as potential targets of Dnmt3b activity, the majority of which were demethylated in Dnmt3b -/- lymphomas, but not in Dnmt3b -/- pretumor thymocytes, implicating Dnmt3b in maintenance of cytosine methylation in cancer. Functional analysis identified the gene Gm128 (which we termed herein methylated in normal thymocytes [Ment]) as a target of Dnmt3b activity. We found that Ment was gradually demethylated and overexpressed during tumor progression in Dnmt3b -/- lymphomas. Similarly, MENT was overexpressed in 67{\%} of human lymphomas, and its transcription inversely correlated with methylation and levels of DNMT3B. Importantly, knockdown of Ment inhibited growth of mouse and human cells, whereas overexpression of Ment provided Dnmt3b +/+ cells with a proliferative advantage. Our findings identify Ment as an enhancer of lymphomagenesis that contributes to the tumor suppressor function of Dnmt3b and suggest it could be a potential target for anticancer therapies.",
author = "Hlady, {Ryan A.} and Slavomira Novakova and Jana Opavska and Klinkebiel, {David L} and Peters, {Staci L.} and Juraj Bies and Jay Hannah and Javeed Iqbal and Anderson, {Kristi M.} and Siebler, {Hollie M.} and Smith, {Lynette M} and Greiner, {Timothy Charles} and Bastola, {Dhundy Raj} and Joshi, {Shantaram S} and Oksana Lockridge and Simpson, {Melanie A.} and Felsher, {Dean W.} and Wagner, {Kay Uwe} and Chan, {Wing C.} and Christman, {Judith K.} and Rene Opavsky",
year = "2012",
month = "1",
day = "3",
doi = "10.1172/JCI57292",
language = "English (US)",
volume = "122",
pages = "163--177",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis

AU - Hlady, Ryan A.

AU - Novakova, Slavomira

AU - Opavska, Jana

AU - Klinkebiel, David L

AU - Peters, Staci L.

AU - Bies, Juraj

AU - Hannah, Jay

AU - Iqbal, Javeed

AU - Anderson, Kristi M.

AU - Siebler, Hollie M.

AU - Smith, Lynette M

AU - Greiner, Timothy Charles

AU - Bastola, Dhundy Raj

AU - Joshi, Shantaram S

AU - Lockridge, Oksana

AU - Simpson, Melanie A.

AU - Felsher, Dean W.

AU - Wagner, Kay Uwe

AU - Chan, Wing C.

AU - Christman, Judith K.

AU - Opavsky, Rene

PY - 2012/1/3

Y1 - 2012/1/3

N2 - DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals. DNA methylation contributes to the epigenetic control of gene transcription and is deregulated in virtually all human tumors. To better understand the generation of cancer-specific methylation patterns, we genetically inactivated Dnmt3b in a mouse model of MYC-induced lymphomagenesis. Ablation of Dnmt3b function using a conditional knockout in T cells accelerated lymphomagenesis by increasing cellular proliferation, which suggests that Dnmt3b functions as a tumor suppressor. Global methylation profiling revealed numerous gene promoters as potential targets of Dnmt3b activity, the majority of which were demethylated in Dnmt3b -/- lymphomas, but not in Dnmt3b -/- pretumor thymocytes, implicating Dnmt3b in maintenance of cytosine methylation in cancer. Functional analysis identified the gene Gm128 (which we termed herein methylated in normal thymocytes [Ment]) as a target of Dnmt3b activity. We found that Ment was gradually demethylated and overexpressed during tumor progression in Dnmt3b -/- lymphomas. Similarly, MENT was overexpressed in 67% of human lymphomas, and its transcription inversely correlated with methylation and levels of DNMT3B. Importantly, knockdown of Ment inhibited growth of mouse and human cells, whereas overexpression of Ment provided Dnmt3b +/+ cells with a proliferative advantage. Our findings identify Ment as an enhancer of lymphomagenesis that contributes to the tumor suppressor function of Dnmt3b and suggest it could be a potential target for anticancer therapies.

AB - DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals. DNA methylation contributes to the epigenetic control of gene transcription and is deregulated in virtually all human tumors. To better understand the generation of cancer-specific methylation patterns, we genetically inactivated Dnmt3b in a mouse model of MYC-induced lymphomagenesis. Ablation of Dnmt3b function using a conditional knockout in T cells accelerated lymphomagenesis by increasing cellular proliferation, which suggests that Dnmt3b functions as a tumor suppressor. Global methylation profiling revealed numerous gene promoters as potential targets of Dnmt3b activity, the majority of which were demethylated in Dnmt3b -/- lymphomas, but not in Dnmt3b -/- pretumor thymocytes, implicating Dnmt3b in maintenance of cytosine methylation in cancer. Functional analysis identified the gene Gm128 (which we termed herein methylated in normal thymocytes [Ment]) as a target of Dnmt3b activity. We found that Ment was gradually demethylated and overexpressed during tumor progression in Dnmt3b -/- lymphomas. Similarly, MENT was overexpressed in 67% of human lymphomas, and its transcription inversely correlated with methylation and levels of DNMT3B. Importantly, knockdown of Ment inhibited growth of mouse and human cells, whereas overexpression of Ment provided Dnmt3b +/+ cells with a proliferative advantage. Our findings identify Ment as an enhancer of lymphomagenesis that contributes to the tumor suppressor function of Dnmt3b and suggest it could be a potential target for anticancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=84855433323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855433323&partnerID=8YFLogxK

U2 - 10.1172/JCI57292

DO - 10.1172/JCI57292

M3 - Article

C2 - 22133874

AN - SCOPUS:84855433323

VL - 122

SP - 163

EP - 177

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -